UY27695A1 - Compuestos que modulan la actividad de ppar. - Google Patents
Compuestos que modulan la actividad de ppar.Info
- Publication number
- UY27695A1 UY27695A1 UY27695A UY27695A UY27695A1 UY 27695 A1 UY27695 A1 UY 27695A1 UY 27695 A UY27695 A UY 27695A UY 27695 A UY27695 A UY 27695A UY 27695 A1 UY27695 A1 UY 27695A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- ppar
- activity
- modulate
- describes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta invención describe compuestos que alteran la actividad de PPAR. La invención también describe sales farmacéuticamente aceptables de los compuestos, composiciones farmacéuticamente aceptables que comprenden los compuestos o sus sales, y procedimientos para usarlos como agentes terapéuticos para el tratamiento o prevención de la hiperlipidemia e hipercolesterolemia en un mamifero. La presente invención también describe procedimientos para la preparación de los compuestos descriptos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36240202P | 2002-03-07 | 2002-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27695A1 true UY27695A1 (es) | 2003-10-31 |
Family
ID=27789157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27695A UY27695A1 (es) | 2002-03-07 | 2003-03-06 | Compuestos que modulan la actividad de ppar. |
Country Status (29)
Country | Link |
---|---|
US (1) | US20030207924A1 (es) |
EP (1) | EP1482935B1 (es) |
JP (1) | JP2005528348A (es) |
KR (1) | KR20040091693A (es) |
AP (1) | AP2004003124A0 (es) |
AR (1) | AR038881A1 (es) |
AT (1) | ATE405260T1 (es) |
AU (1) | AU2003206059A1 (es) |
BR (1) | BR0308277A (es) |
CA (1) | CA2478520A1 (es) |
CO (1) | CO5601012A2 (es) |
DE (1) | DE60323060D1 (es) |
EA (1) | EA200400943A1 (es) |
EC (1) | ECSP045285A (es) |
ES (1) | ES2310650T3 (es) |
HN (1) | HN2003000090A (es) |
IS (1) | IS7377A (es) |
MA (1) | MA27181A1 (es) |
MX (1) | MXPA04007564A (es) |
NO (1) | NO20044242L (es) |
OA (1) | OA12780A (es) |
PA (1) | PA8567801A1 (es) |
PE (1) | PE20030989A1 (es) |
PL (1) | PL372969A1 (es) |
TN (1) | TNSN04168A1 (es) |
TW (1) | TW200305403A (es) |
UY (1) | UY27695A1 (es) |
WO (1) | WO2003074050A1 (es) |
ZA (1) | ZA200406068B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
CN1791592B (zh) * | 2003-05-19 | 2012-07-04 | Irm责任有限公司 | 免疫抑制剂化合物和组合物 |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
BRPI0508098A (pt) | 2004-02-27 | 2007-07-17 | Amgen Inc | compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos |
ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
AU2012200214B2 (en) * | 2004-05-14 | 2013-10-24 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
CN1997633A (zh) * | 2004-05-25 | 2007-07-11 | 麦它波莱克斯股份有限公司 | 作为ppar调节剂的取代的***及其制备方法 |
WO2005115384A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
JP4869338B2 (ja) * | 2005-05-07 | 2012-02-08 | ソウル ナショナル ユニバーシティー インダストリー ファンデーション | ペルオキシソーム増殖因子活性化受容体δリガンドの製造方法及びこれを製造するための中間体 |
US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
ES2449618T3 (es) | 2005-06-30 | 2014-03-20 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de PPAR-delta |
JP5084503B2 (ja) * | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
WO2007033002A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
EA015717B1 (ru) | 2005-12-22 | 2011-10-31 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Феноксиуксусные кислоты в качестве активаторов ppar дельта |
JP2009132620A (ja) * | 2006-03-07 | 2009-06-18 | Astellas Pharma Inc | フェニルチアゾール誘導体 |
CA2645719A1 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
AU2007292816B2 (en) | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
US7714008B2 (en) | 2006-09-07 | 2010-05-11 | Amgen Inc. | Heterocyclic GPR40 modulators |
JP2010524932A (ja) | 2007-04-16 | 2010-07-22 | アムジエン・インコーポレーテツド | 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質 |
US8030354B2 (en) | 2007-10-10 | 2011-10-04 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
CA2708391A1 (en) * | 2007-12-13 | 2009-06-25 | Sri International | Ppar-delta ligands and methods of their use |
US8217064B2 (en) | 2007-12-20 | 2012-07-10 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
ES2450567T3 (es) | 2008-10-15 | 2014-03-25 | Amgen, Inc | Moduladores de GPR40 espirocíclicos |
BR112012021515A2 (pt) * | 2010-02-25 | 2016-07-05 | Snu R&Db Foundation | derivado de selenazol tendo ligantes os quais ativam o receptor ativado de proliferador de peroxissomo (ppar), método de preparação do mesmo e o uso dos compostos químicos |
EP3043789B1 (en) | 2013-09-09 | 2020-07-08 | vTv Therapeutics LLC | Use of a ppar-delta agonists for treating muscle atrophy |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
KR20000068151A (ko) * | 1996-08-19 | 2000-11-25 | 미즈노 마사루 | 프로피온산 유도체 및 그의 용도 |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
GB0031107D0 (en) * | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
EP1345916A1 (en) * | 2000-12-20 | 2003-09-24 | Glaxo Group Limited | Substituted oxazoles and thiazoles as hppar alpha agonists |
GB0111523D0 (en) * | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
HUP0400268A2 (hu) * | 2001-06-07 | 2004-07-28 | Eli Lilly And Co. | Peroxiszóma proliferátorral aktivált receptorokat (PPAR) módosító hatóanyagok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
-
2002
- 2002-12-20 US US10/324,148 patent/US20030207924A1/en not_active Abandoned
-
2003
- 2003-02-24 EP EP03702943A patent/EP1482935B1/en not_active Expired - Lifetime
- 2003-02-24 KR KR10-2004-7013951A patent/KR20040091693A/ko not_active Application Discontinuation
- 2003-02-24 AP APAP/P/2004/003124A patent/AP2004003124A0/en unknown
- 2003-02-24 WO PCT/IB2003/000708 patent/WO2003074050A1/en active IP Right Grant
- 2003-02-24 PL PL03372969A patent/PL372969A1/xx not_active Application Discontinuation
- 2003-02-24 AT AT03702943T patent/ATE405260T1/de not_active IP Right Cessation
- 2003-02-24 DE DE60323060T patent/DE60323060D1/de not_active Expired - Fee Related
- 2003-02-24 ES ES03702943T patent/ES2310650T3/es not_active Expired - Lifetime
- 2003-02-24 EA EA200400943A patent/EA200400943A1/ru unknown
- 2003-02-24 AU AU2003206059A patent/AU2003206059A1/en not_active Abandoned
- 2003-02-24 CA CA002478520A patent/CA2478520A1/en not_active Abandoned
- 2003-02-24 BR BR0308277-6A patent/BR0308277A/pt not_active IP Right Cessation
- 2003-02-24 MX MXPA04007564A patent/MXPA04007564A/es active IP Right Grant
- 2003-02-24 OA OA1200400232A patent/OA12780A/en unknown
- 2003-02-24 JP JP2003572567A patent/JP2005528348A/ja not_active Abandoned
- 2003-02-27 PA PA20038567801A patent/PA8567801A1/es unknown
- 2003-03-04 PE PE2003000210A patent/PE20030989A1/es not_active Application Discontinuation
- 2003-03-05 AR ARP030100737A patent/AR038881A1/es unknown
- 2003-03-06 TW TW092104790A patent/TW200305403A/zh unknown
- 2003-03-06 UY UY27695A patent/UY27695A1/es not_active Application Discontinuation
- 2003-03-06 HN HN2003000090A patent/HN2003000090A/es unknown
-
2004
- 2004-07-29 IS IS7377A patent/IS7377A/is unknown
- 2004-07-29 ZA ZA200406068A patent/ZA200406068B/en unknown
- 2004-08-24 CO CO04082302A patent/CO5601012A2/es not_active Application Discontinuation
- 2004-08-30 MA MA27839A patent/MA27181A1/fr unknown
- 2004-09-03 TN TNP2004000168A patent/TNSN04168A1/fr unknown
- 2004-09-07 EC EC2004005285A patent/ECSP045285A/es unknown
- 2004-10-06 NO NO20044242A patent/NO20044242L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR0308277A (pt) | 2004-12-28 |
HN2003000090A (es) | 2004-05-05 |
AR038881A1 (es) | 2005-02-02 |
PE20030989A1 (es) | 2003-11-29 |
EP1482935A1 (en) | 2004-12-08 |
NO20044242L (no) | 2004-10-06 |
TW200305403A (en) | 2003-11-01 |
MXPA04007564A (es) | 2004-11-10 |
MA27181A1 (fr) | 2005-01-03 |
US20030207924A1 (en) | 2003-11-06 |
PL372969A1 (en) | 2005-08-08 |
TNSN04168A1 (fr) | 2007-03-12 |
ECSP045285A (es) | 2004-10-26 |
KR20040091693A (ko) | 2004-10-28 |
EA200400943A1 (ru) | 2005-02-24 |
CA2478520A1 (en) | 2003-09-12 |
ES2310650T3 (es) | 2009-01-16 |
ATE405260T1 (de) | 2008-09-15 |
DE60323060D1 (de) | 2008-10-02 |
JP2005528348A (ja) | 2005-09-22 |
CO5601012A2 (es) | 2006-01-31 |
AP2004003124A0 (en) | 2004-09-30 |
EP1482935B1 (en) | 2008-08-20 |
WO2003074050A1 (en) | 2003-09-12 |
ZA200406068B (en) | 2005-09-06 |
OA12780A (en) | 2006-07-07 |
PA8567801A1 (es) | 2003-11-12 |
IS7377A (is) | 2004-07-29 |
AU2003206059A1 (en) | 2003-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27695A1 (es) | Compuestos que modulan la actividad de ppar. | |
UY27704A1 (es) | Compuestos que modulan la actividad de ppar | |
UY27696A1 (es) | Compuestos que modulan la actividad de ppar | |
DOP2003000620A (es) | Compuestos que modulan la actividad de ppar y procedimientos para su preparación | |
DOP2004000881A (es) | Compuestos que modulan la actividad de ppar y procedimientos de preparacion | |
GT200500158A (es) | Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa | |
ECSP045098A (es) | Procedimientos para tratar enfermedades neovasculares oculares | |
ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
DK1689724T3 (da) | Quinazolinonforbindelser som anticancermidler | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
PA8680701A1 (es) | Derivados de oxindol | |
UY27226A1 (es) | Pirazolopirimidinas como agentes terapéuticos | |
CR10314A (es) | Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina | |
CR8497A (es) | Derivados de azepinoindol como agentes farmaceuticos | |
UY30460A1 (es) | Compuestos terapéuticos | |
CR9903A (es) | Compuestos antihipercolesterolemicos | |
CO2019005552A2 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
AR047922A1 (es) | Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos | |
CL2019000768A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
HN2003000063A (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades. | |
CL2007002381A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis | |
ECSP045131A (es) | Inhibidores de fosfolipasa a2 citosólica | |
CY1110027T1 (el) | Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων | |
BR0008603A (pt) | Método para tratamento de copd | |
DOP2003000593A (es) | Compuestos que modulan la actividad de ppar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150126 |